Synergy Pharmaceuticals Inc. Raises $200M Rule 144A Offering of 7.50% Convertible Senior Notes
Sichenzia Ross Friedman Ference LLP Represents Synergy Pharmaceuticals Inc. in $200M Rule 144A Offering of 7.50% Convertible Senior Notes
New York, NY – (Global Newswire, November 5, 2014) – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced that it represented Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical developer of drugs to treat gastrointestinal disorders and diseases, in a Rule 144A offering of $200 million of 7.50% Convertible Senior notes. The notes are convertibles into shares of Synergy Pharmaceutical’s common stock at a conversion price of approximately $3.11 per share.
The SRFF team was led by Partner Jeffrey J. Fessler.
- 合伙人安德鲁·M·J·伯恩斯坦（Andrew M.J. Bernstein）将为劳伦（Lawline）撰写CLE“为陪审团做准备” - January 11, 2021
- Sichenzia Ross Ference LLP代表KULR Technology Group，Inc.进行800万美元的注册直接发行 - January 4, 2021
- Sichenzia Ross Ference LLP代表SunHydrogen完成900万美元的认股权证交易 - December 30, 2020